作者
Giovanna Lucchini, Martino Introna, Erica Dander, Attilio Rovelli, Adriana Balduzzi, Sonia Bonanomi, Agnese Salvadè, Chiara Capelli, Daniela Belotti, Giuseppe Gaipa, Paolo Perseghin, Paola Vinci, Edoardo Lanino, Patrizia Chiusolo, Maria Grazia Orofino, Sarah Marktel, Jose Golay, Alessandro Rambaldi, Andrea Biondi, Giovanna D'Amico, Ettore Biagi
发表日期
2010/9/1
期刊
Biology of blood and marrow transplantation
卷号
16
期号
9
页码范围
1293-1301
出版商
Elsevier
简介
Despite advances in graft-versus-host-disease (GVHD) treatment, it is estimated that overall survival (OS) at 2 years for hematopoietic cell transplantation (HCT) recipients who experience steroid-resistant GVHD is 10%. Among recent therapeutic approaches for GVHD treatment, mesenchymal stromal cells (MSCs) hold a key position. We describe a multicenter experience of 11 pediatric patients diagnosed with acute or chronic GVHD (aGVHD, cGVHD) treated for compassionate use with GMP-grade unrelated HLA-disparate donors' bone marrow-derived MSCs, expanded in platelet-lysate (PL)-containing medium. Eleven patients (aged 4-15 years) received intravenous (i.v.) MSCs for aGVHD or cGVHD, which was resistant to multiple lines of immunosuppression. The median dose was 1.2 × 106/kg (range: 0.7-3.7 × 106/kg). No acute side effects were observed, and no late side effects were reported at a median …
学术搜索中的文章
G Lucchini, M Introna, E Dander, A Rovelli, A Balduzzi… - Biology of blood and marrow transplantation, 2010